Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

← catalyst calendar

NCT06690177 · readout in 497 d

Sponsored by MediWound Ltd (industry) · MDWD — their whole pipeline →.

Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
45estimated
Sites
2
Countries
Poland, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-04-30estimatedWhen the study began enrolling
Primary completion2027-12-30estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2028-09-30estimatedThe whole study's end, after follow-up
First posted2024-11-15actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2024-11-15actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Venus Leg Ulcers

Interventions

  • Drug: EscharEx (EX-03)
  • Drug: Placebo (Gel vehicle)

Primary outcomes

what the primary-completion date above is the date OF
Incidence (number of patients) of target wound related AEs throughout the trial
measured Throughout the study (week 2- week 15)
Number of patients with Clinically significant changes in vital signs during the Daily Visits Period,
measured Weeks 2-3 (14 days)
Number of patients with Clinically significant changes in clinical laboratory parameters
measured Weeks 2-3 (14 days)
Time to complete wound closure
measured Weeks 2-15
Incidence of complete wound closure
measured 2-15 weeks

Permalink · MDWD's whole pipeline · Catalyst calendar · Every registered study · What changed